Selbyville, Delaware, Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market Report available at MarketStudyReport.com gives an industry overview of the Non-Alcoholic Steatohepatitis (Nash) Biomarker, which covers product scope, market revenue, opportunities, growth rate, sales volumes and figures. The report also explores the worldwide players of the market and is segmented by region, type and application with forecast to 2028. According to a Market Research’s report, the global market for non-alcoholic steatohepatitis (NASH) biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.
The growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path. Besides, an increase in awareness regarding non-alcoholic fatty liver disease is opening new avenues for the NASH biomarker market over the projected period.
However, side-effects of NASH therapeutics, along with the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.
The global market includes the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.
The Asia-Pacific is expected to observe the fastest growth rate in the non-alcoholic steatohepatitis biomarker market during the forecast period. The region’s growth can be attributed to the advancements in the healthcare infrastructure, the surge in the prevalence of NASH, and improvement in economic conditions. Along with this, the growing healthcare awareness in emerging economies, including India and China, is expected to further influence the growth of the NASH biomarker market around the APAC region in the upcoming years.
The prominent companies engaged in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca, Zydus Cadila, and Siemens Healthineers.
Allergan is engaged in developing, manufacturing, marketing, and distributing specialty, biosimilar, and over-the-country products. Its product portfolio includes cenicriviroc that blocks two chemokine receptors involved in inflammatory and fibrogenic pathways. This product’s phase 3 AURORA plans to enroll a large number of patients suffering from NASH. Allergen has operations in numerous regions, such as Asia-Pacific, Europe, and Latin America, serving a wide consumer base. It is headquartered in Dublin, Ireland.
TABLE OF CONTENTS
- IMPACT OF COVID-19
- KEY INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF BUYERS
- BARGAINING POWER OF SUPPLIERS
- THREAT OF COMPETITIVE RIVALRY
- KEY MARKET STRATEGIES
- MARKET OUTLOOK – BY PRODUCT
- MARKET OUTLOOK – BY APPLICATION
- MARKET – REGIONAL OUTLOOK
- COMPETITIVE LANDSCAPE
- RESEARCH METHODOLOGY & SCOPE
- RESEARCH SCOPE & DELIVERABLES
- RESEARCH METHODOLOGY
Market Study Report, LLC. is a hub for Market intelligence products and services. We streamline the purchase of your Market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place. Our customers partner with Market Study Report, LLC. to ease their search and evaluation of Market intelligence products and services and in turn focus on their company’s core activities. If you are looking for research reports on global or regional Markets, competitive information, emerging Markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
US Toll Free: 1-866-764-2150
Email: [email protected]